基线18F-FDG PET/CT或可预测华氏巨球蛋白血症/淋巴浆细胞淋巴瘤患者一线治疗后的预后
回顾性纳入33例新诊断华氏巨球蛋白血症/淋巴浆细胞淋巴瘤(WM/LPL)患者,于基线行18F-FDG PET/CT并接受积极治疗。结果显示,TLG>291.28 SUVbw*mL和MTV>108.78 mL是无进展生存期(PFS)和至下次治疗时间(TTNT)的独立预后因素。
要点
- TLG>291.28 SUVbw*mL和MTV>108.78 mL是无进展生存期(PFS)的独立预后因素(HR 3.06)。
- TLG>291.28 SUVbw*mL和MTV>108.78 mL是至下次治疗时间(TTNT)的独立预后因素(HR 10.01)。
- 基线18F-FDG PET/CT代谢指标TLG和MTV或可预测WM/LPL患者一线治疗后的预后。
核心结论
- 基线18F-FDG PET/CT的TLG和MTV代谢指标是预测WM/LPL患者PFS和TTNT的独立预后因素。
研究设计与样本
- 回顾性研究纳入33例新诊断WM/LPL患者,均行基线18F-FDG PET/CT并接受积极治疗。
- 测量基线18F-FDG PET/CT半定量指标:总病灶糖酵解(TLG)、代谢肿瘤体积(MTV)和SUVmax。
- 随访至少3年或至终点,终点定义为无进展生存期(PFS)和至下次治疗时间(TTNT)。
主要发现
- 一线治疗总缓解率为84.8%(28/33)。
- 3年PFS率和总生存率分别为56.3%和89.3%。
- PFS<36个月和TTNT<36个月患者的TLG和MTV显著高于PFS≥36个月和TTNT≥36个月者(P<0.05)。
- PFS<36个月患者的SUVmax显著高于PFS≥36个月者(P=0.033)。
- Kaplan-Meier分析显示TLG>291.28 SUVbw*mL和MTV>108.78 mL预测更短的PFS(P=0.003)和TTNT(P=0.002)。
关键数值与推荐
- 预测PFS<36个月的最佳截断值:TLG>291.28 SUVbw*mL、MTV>108.78 mL、SUVmax>3.16。
- 多因素分析中,TLG>291.28 SUVbw*mL和MTV>108.78 mL是更短PFS的独立预测因素(HR 3.06;95%CI 1.09-8.57;P=0.033)。
- 多因素分析中,TLG>291.28 SUVbw*mL和MTV>108.78 mL是更短TTNT的独立预测因素(HR 10.01;95%CI 2.56-39.22;P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The outcome of patients with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is variable. We aim to study if baseline 18 F-FDG PET/CT has some prognostic significance in WM/LPL. METHODS: Thirty-three patients with newly diagnosed WM/LPL who underwent baseline 18 F-FDG PET/CT and received active treatment thereafter were recruited in this retrospective study. Semiquantitative indices of baseline 18 F-FDG PET/CT were measured as total lesion glycolysis (TLG), metabolic tumor volume (MTV), and SUV max . The patients were followed up for at least 3 years or until reaching the endpoint, which were defined as progression-free survival (PFS) and the time to next treatment (TTNT). RESULTS: The overall response rate of the first-line treatment in the recruited patients was 84.8% (28/33). The 3-year PFS and overall survival rates were 56.3% and 89.3%, respectively. Patients with PFS <36 months and TTNT <36 months showed TLG and MTV significantly higher than those with PFS ≥36 months and TTNT ≥36 months ( P < 0.05). SUV max in patients with PFS <36 months was significantly higher than those with PFS ≥36 months ( P = 0.033). Receiver operating characteristic analysis demonstrated that cutoff values of TLG >291.28 SUVbw * mL, MTV >108.78 mL, and SUV max >3.16 were optimal for predicting PFS <36 months. Kaplan-Meier analysis showed that TLG >291.28 SUVbw * mL and MTV >108.78 mL were predictive for shorter PFS ( P = 0.003) and TTNT ( P = 0.002). In multivariate analysis, TLG >291.28 SUVbw * mL and MTV >108.78 mL were independent predictors for shorter PFS (hazard ratio, 3.06; 95% confidence interval, 1.09-8.57; P = 0.033) and TTNT (hazard ratio, 10.01; 95% confidence interval, 2.56-39.22; P = 0.001). CONCLUSIONS: The metabolic indices of TLG and MTV in baseline 18 F-FDG PET/CT were independent prognostic factors to predict PFS and TTNT in patients with WM/LPL.
引用
- Pan Q, Cao X, Luo Y, et al. Baseline 18 F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. Clin Nucl Med. 2022. PMID: 35961637. doi:10.1097/RLU.0000000000004362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。